{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:11:09Z","timestamp":1756894269698,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Microlife"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Aims<\/jats:title>\n<jats:p>Undiagnosed atrial fibrillation (AF) accounts for 6% of all strokes, therefore early detection and treatment of the arrhythmia are paramount. Previous research has illustrated that the Microlife WatchBPO3 AFIB, an automated blood pressure (BP) monitor with an inbuilt AF algorithm, accurately detects permanent AF. Currently, limited data exist on whether the modified BP monitor is able to detect paroxysmal AF (PAF). Therefore, this study aims to assess the accuracy of the Microlife WatchBPO3 AFIB monitor to detect PAF against a pacemaker reference standard over a 24-h period.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and results<\/jats:title>\n<jats:p>Forty-eight patients with a pacemaker implanted for sick sinus syndrome and previously documented fast AF participated. Sensitivity of the atrial pacemaker lead was set to allow detection of signals of\u2009\u2265\u20090.5\u00a0mV. Patients engaged in their normal daily routine whilst wearing the modified BP monitor. The modified BP monitor demonstrated an overall sensitivity of 76.0% and specificity of 80.8% for detecting PAF. This sensitivity and specificity increased to 100% and 83.1%, respectively, for patients that achieved more than 80% successful BP readings. Compared to day-time readings, night-time readings also demonstrated a lower proportion of movement artefact (14.4% vs. 3.4%), and therefore, a higher sensitivity and specificity of 100% and 84.9%, respectively, for detecting PAF.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The Microlife WatchBPO3 AFIB device has an acceptable diagnostic accuracy to detect PAF; however, movement artefact affects the accuracy of the readings. This modified BP monitor may potentially be useful as a screening tool for AF in patients at high risk of developing stroke.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00392-019-01567-y","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:05:54Z","timestamp":1573124754000},"page":"802-809","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation"],"prefix":"10.1007","volume":"109","author":[{"given":"Nina","family":"Huppertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5604-9378","authenticated-orcid":false,"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"key":"1567_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/07853890701320662","volume":"39","author":"I Savelieva","year":"2007","unstructured":"Savelieva I, Bajpai A, Camm AJ (2007) Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med 39:371\u2013391","journal-title":"Ann Med"},{"key":"1567_CR2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","volume":"36","author":"C Marini","year":"2005","unstructured":"Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36:1115\u20131119","journal-title":"Stroke"},{"key":"1567_CR3","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1161\/STROKEAHA.106.478685","volume":"38","author":"J Liao","year":"2007","unstructured":"Liao J, Khalid Z, Scallan C, Morillo C, O'Donnell M (2007) Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 38:2935\u20132940","journal-title":"Stroke"},{"key":"1567_CR4","doi-asserted-by":"crossref","unstructured":"Stott DJ, Dewar RI, Garratt CJ, Griffith KE, Harding NJ, James MA, Lane DA, Petty DR, Smith PA, Somerville MH, Trueland J (2012) RCPE UK Consensus Conference on 'Approaching the comprehensive management of atrial fibrillation: evolution or revolution? J R Coll Physicians Edinb 42:3\u20134.","DOI":"10.4997\/JRCPE.2012.S01"},{"key":"1567_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.amjcard.2013.01.331","volume":"111","author":"J Wiesel","year":"2013","unstructured":"Wiesel J, Abraham S, Messineo FC (2013) Screening for asymptomatic atrial fibrillation while monitoring the blood pressure at home: trial of regular versus irregular pulse for prevention of stroke (TRIPPS 2.0). Am J Cardiol 111:1598\u20131601","journal-title":"Am J Cardiol"},{"issue":"4","key":"1567_CR6","doi-asserted-by":"publisher","first-page":"e004565","DOI":"10.1136\/bmjopen-2013-004565","volume":"20","author":"K Kearley","year":"2014","unstructured":"Kearley K, Selwood M, Van Den Bruel A, Thompson M, Mant D, Hobbs FDR, Fitzmaurice D, Heneghan C (2014) Triage tests for identifying atrial fibrillation in primary care: a diagnostic accuracy study comparing single-lead ECG and modified BP monitors. BMJ Open 20(4):e004565","journal-title":"BMJ Open"},{"key":"1567_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","volume":"107","author":"TV Glotzer","year":"2003","unstructured":"Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R, Cook J, Paraschos A, Love J, Radoslovich G, Lee KL, Lamas GA, Investigators MOST (2003) Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST). Circulation 107:1614\u20131619","journal-title":"Circulation"},{"key":"1567_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/bmj.320.7242.1128","volume":"230","author":"E O\u2019Brien","year":"2000","unstructured":"O\u2019Brien E, Coats A, Owens P, Petrie J, Padfield P, Littler W, de Swiet M, Mee F (2000) Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 230:1128\u20131134","journal-title":"BMJ"},{"key":"1567_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1540-8159.2004.00499.x","volume":"27","author":"J Wiesel","year":"2004","unstructured":"Wiesel J, Wiesel D, Suri R, Messineo FC (2004) The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients. Pacing Clin Electrophysiol 27:639\u2013643","journal-title":"Pacing Clin Electrophysiol"},{"key":"1567_CR10","first-page":"25","volume-title":"Modern pacemakers\u2014present and future","author":"M Santomauro","year":"2011","unstructured":"Santomauro M, Duilio C, Riganti C, Di Mauro P, Iappicca G, Auricchio L, Borrelli A, Filardi PP (2011) Different automatic mode switching in DDDR pacemakers. In: Das MM (ed) Modern pacemakers\u2014present and future, 1st edn. InTech, Croatia, pp 25\u201336","edition":"1"},{"key":"1567_CR11","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1046\/j.1540-8167.2004.03537.x","volume":"15","author":"RS Passman","year":"2004","unstructured":"Passman RS, Weinberg KM, Freher M, Schaechter A, Goldberger JJ, Kadish AH (2004) Accuracy of mode switch algorithms for detection of atrial tachyarrhythmias. J Cardiovasc Electrophysiol 15:773\u2013777","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1567_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/jama.282.6.539","volume":"282","author":"JA Staessen","year":"1999","unstructured":"Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, De Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282:539\u2013546","journal-title":"JAMA"},{"key":"1567_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/jhh.2009.5","volume":"23","author":"GS Stergiou","year":"2009","unstructured":"Stergiou GS, Karpettas N, Protogerou A, Nasothimiou EG, Kyriakidis M (2009) Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. J Hum Hypertens 23:654\u2013658","journal-title":"J Hum Hypertens"},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1097\/HJH.0b013e328363e964","volume":"31","author":"E O'Brien","year":"2009","unstructured":"O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shannan A, Staessen JA, vanMontfrans G, Verdeccia P, Waeber B, Wang J, Zanchetti A, Zhang Y, European Society of Hypertension Working Group on Blood Pressure Monitoring (2009) European society of hypertension position paper on ambulatory blood pressure monitoring. J Hum Hypertens 31:1731\u20131768","journal-title":"J Hum Hypertens"},{"key":"1567_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1161\/01.HYP.21.4.504","volume":"21","author":"WB White","year":"1993","unstructured":"White WB, Berson AS, Robbins C, Jamieson MJ, Prisant LM, Roccella E, Sheps SG (1993) National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. J Hypertens 21:504\u2013509","journal-title":"J Hypertens"},{"key":"1567_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/ajh.2009.98","volume":"22","author":"J Wiesel","year":"2009","unstructured":"Wiesel J, Fitzig L, Herschman Y, Messineo FC (2009) Detection of atrial fibrillation using a modified microlife blood pressure monitor. Am J Hypertens 22:848\u2013852","journal-title":"Am J Hypertens"},{"key":"1567_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/HYPERTENSIONAHA.117.10797","volume":"72","author":"A Kollias","year":"2018","unstructured":"Kollias A, Destounis A, Kalogeropoulos P, Kyriakoulis KG, Ntineri A, Stergiou GS (2018) Atrial fibrillation detection during 24-h ambulatory blood pressure monitoring: comparison with 24-h electrocardiography. J Hypertens 72:110\u2013115","journal-title":"J Hypertens"},{"key":"1567_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","volume":"2","author":"TV Glotzer","year":"2009","unstructured":"Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler PD (2009) The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2:474\u2013480","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1567_CR19","doi-asserted-by":"publisher","first-page":"e013685","DOI":"10.1136\/bmjopen-2016-013685","volume":"7","author":"PH Chan","year":"2017","unstructured":"Chan PH, Wong CK, Pun L, Wong YF, Wong MM, Chu DW (2017) Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting. BMJ Open 7:e013685","journal-title":"BMJ Open"},{"key":"1567_CR20","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.amjcard.2017.07.016","volume":"20","author":"J Wiesel","year":"2017","unstructured":"Wiesel J, Salomone TJ (2017) Screening for atrial fibrillation in patients \u2265 65 years using an automatic blood pressure monitor in a skilled nursing facility. Am J Cardiol 20:1322\u20131324","journal-title":"Am J Cardiol"},{"key":"1567_CR21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1160\/TH16-11-0876","volume":"117","author":"GYH Lip","year":"2017","unstructured":"Lip GYH, Freedman B, De Caterina R, Potpara TS (2017) Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. J Thromb Haemost 117:1230\u20131239","journal-title":"J Thromb Haemost"},{"key":"1567_CR22","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L (2018) Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest 154:1121\u20131201","journal-title":"Chest"},{"key":"1567_CR23","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.1540-8159.1998.tb00125.x","volume":"21","author":"K Seidl","year":"1998","unstructured":"Seidl K, Meisel E, VanAgt E, Ottenhoff F, Hess M, Hauer B, Zahn R, Senges J (1998) Is the atrial high rate episode diagnostic feature reliable in detecting paroxysmal episodes of atrial tachyarrhythmias? Pacing Clin Electrophysiol 21:694\u2013700","journal-title":"Pacing Clin Electrophysiol"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:10:24Z","timestamp":1604621424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01567-y","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"type":"print","value":"1861-0684"},{"type":"electronic","value":"1861-0692"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Lane has received investigator-initiated educational grants from Bristol Myers Squibb (BMS) and Boehringer Ingelheim; speaker for Boehringer Ingelheim, Bayer, and BMS\/Pfizer, and consulted for Boehringer Ingelheim, Bayer, BMS\/Pfizer, and Daiichi-Sankyo. Professor Lip has consulted for Bayer\/Janssen, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Microlife, Verseon, and Daiichi-Sankyo; speaker for Bayer, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. Nina Huppertz has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}